Alnylam Pharmaceuticals
ALNY
#653
Rank
A$47.73 B
Marketcap
$370.10
Share price
-7.25%
Change (1 day)
41.51%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : A$6.45 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are A$6.45 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31A$5.94 B9.21%
2022-12-31A$5.44 B29.18%
2021-12-31A$4.21 B35.53%
2020-12-31A$3.10 B127.61%
2019-12-31A$1.36 B252.72%
2018-12-31A$0.38 B32.44%
2017-12-31A$0.29 B-38.47%
2016-12-31A$0.47 B184.27%
2015-12-31A$0.16 B-4.54%
2014-12-31A$0.17 B4.02%
2013-12-31A$0.16 B14.01%
2012-12-31A$0.14 B-7.62%
2011-12-31A$0.15 B-30.91%
2010-12-31A$0.23 B-31.5%
2009-12-31A$0.33 B-32.41%
2008-12-31A$0.49 B48.29%
2007-12-31A$0.33 B584.1%
2006-12-31A$49.26 M-1.44%
2005-12-31A$49.97 M93.72%
2004-12-31A$25.79 M-69.01%
2003-12-31A$83.26 M126%
2002-12-31A$36.84 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
A$0.84 B-86.94%๐Ÿ‡บ๐Ÿ‡ธ USA
A$12.55 B 94.50%๐Ÿ‡บ๐Ÿ‡ธ USA
A$3.68 B-42.99%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.90 B-85.99%๐Ÿ‡บ๐Ÿ‡ธ USA
A$9.18 M-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
A$92.96 B 1,339.91%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$94.13 B 1,358.14%๐Ÿ‡ซ๐Ÿ‡ท France
A$54.73 B 747.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel